Drug Profile
Tinzaparin sodium - LEO Pharma/Novo Nordisk
Alternative Names: Innohep; LogiparinLatest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator LEO Pharma; Novo Nordisk
- Developer LEO Pharma; Ottawa Hospital Research Institute
- Class Antithrombotics; Glycosaminoglycans; Low molecular weight heparins
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Thrombosis
- Phase III Adenocarcinoma
Most Recent Events
- 15 Sep 2021 LEO Pharma completes the phase III TASC trial for Thrombosis in France (SC) (NCT02580773)
- 21 Feb 2019 Chemical structure information added
- 30 Jan 2019 Phase-III clinical trials in Venous thromboembolism (Prevention) in Greece (SC) (EudraCT2018-001230-18)